BioLife maintains an EVIDENCE PAGE on our corporate website with links to presentations, journal articles, abstracts and posters. We currently have over 365 citations and counting! Evidence is searchable by titles and keywords; and provides a tremendous resource for researchers and clinicians looking for relevant information on cell type, variant of optimized biopreservation media (for example: CS5 or CS10), and additional publishing and citation information.
There are a number of reasons one may need to cryopreserve cells. The most recent journal articles added to BioLife’s Cryopreservation Journal Article Evidence illustrate several: Laucher et al. cryopreserved SV-BR-1-GM cells for transport to the process facility for analysis. Rajamani et al. cryopreserved PBMC cells mid-process using CryoStor, enabling coordination of thawing and final processing at a later time. Lin et al. cryopreserved hUC-MSC cells in CryoStor CS 10 that would be used for pre-clinical trials in an animal model of cerebral ischemia.
Lacher, M. D., Bauer, G., Fury, B., Graeve, S., Fledderman, E. L., Petrie, T. D., Coleal-Bergum, D. P., Hackett, T., Perotti, N. H., Kong, Y. Y., Kwok, W. W., Wagner, J. P., Wiseman, C. L., Williams, W. V. SV-BR-1-GM, A Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses An Immune Signature And Directly Activates CD4+ T Lymphocytes. Frontiers In Immunology 2018; 9(776), 1-23. Doi:10.3389/fimmu.2018.00776
Cell line SV-BR-1 was originally derived from a chest wall lesion from a metastatic breast cancer patient. Subsequently, SV-BR-1 was genetically engineered to stably over express GM-CSF, creating cell line SV-BR-1-GM. Irradiated (200 Gy) SV-BR-1-GM cells have been demonstrated to reduce tumor burden administered as a cellular vaccine to study patients with breast cancer in clinical trial NCT00095862. In the current publication, Lacher et al. characterized SV-BR-1-GM to create a “molecular fingerprint” of the cell line. To prepare cells for transport, the SV-BR-1-GM formulation process was modified to cryopreserve freshly expanded cells in CryoStor® CS5 for overnight shipment on dry ice to the process laboratory for FACS analysis.
Rajamani, U., Gross, A. R., Hjelm, B. E., Sequeira, A., Vawter, M. P., Tang, J., Gangalapudi, V., Wang, Y., Andres, A. M., Gottlieb, R. A., Sareen, D. Super-Obese Patient-Derived iPSC Hypothalamic Neurons Exhibit Obesogenic Signatures and Hormone Responses. Cell Stem Cell 2018, Vol. 22(5), 698-712.e9. Doi: 10.1016/j.stem.2018.03.009
Rajamani et al. collected peripheral blood mononuclear cells (PBMCs) from healthy individuals with body mass index (BMI) ≤ 25 and ≥ 50. PBMCs were reprogrammed to create human induced induced pluripotent stem cell (hIPSC) lines. hIPSCs were differentiated into induced hypothalamic-like neurons (iHTNs) which demonstrated characteristics and functions of neurons of the arcuate nucleus in the hypothalamus and responded to exogenous hormone signals. Induced hypothalamic-like neurons at Day 20 following differentiation were frozen in CryoStor® CS10, thawed when needed and cultured for an additional 20 days for assessment of hypothalamic markers and transcriptome signatures.
Willie Lin, Yogi Chang-Yo Hsuan, Mao-Tsun Lin, Ting-Wei Kuo, Cheng-Hsien Lin, Yu-Chin Su, Ko-Chi Niu, Ching-Ping Chang, Hung-Jung Lin. Human Umbilical Cord Mesenchymal Stem Cells Preserve Adult Newborn Neurons and Reduce Neurological Injury after Cerebral Ischemia by Reducing the Number of Hypertrophic Microglia/Macrophages. Cell Transplantation 2017 Nov; 26(11): 1798–1810. Doi: 10.1177/0963689717728936
In a rodent model of ischemic stroke, activated hypertrophic microglia impair neurogenesis. The authors sought to test the hypothesis that human umbilical cord-derived mesenchymal stem cells can reduce neurological damage following cerebral ischemia by decreasing the number of hypertrophic microglia/macrophages. Non-adherent human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) were isolated and cryopreserved in CryoStor CS10 for storage in vapor phase liquid nitrogen. For use, hUC-MSCs were thawed, placed in cell culture, and harvested when the culture became 80% confluent, washed, counted and resuspended to the appropriate concentration in normal saline. hUC-MSCs suspended in saline were injected intravenously into male Sprague-Dawley rats surgically treated to model transient ischemic stroke.
What are your cell biopreservation needs? Search our Evidence Library or Ask The Scientists to discuss how incorporation of BioLife biopreservation reagents can lead to optimization of your cell processing requirements.
In support of our Mission of Biopreservation Best Practices, please note that our Senior Vice President and Chief Technology Officer, Aby J. Mathew, PhD, part of the founding BioLife team and co-developer of our biopreservation media technology, and his team of scientists, are always available to answer technical questions, optimize protocols, and consult on best practices. Access their years of biopreservation expertise through our “Ask The Scientists” webpage .